Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis

BACKGROUND: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. METHODS: We compared two groups of patients with a fairly similar prognosis either receiving Aflibercept or R...

Descripción completa

Detalles Bibliográficos
Autores principales: Böhni, Sophie C., Bittner, Mario, Howell, Jeremy P., Bachmann, Lucas M., Faes, Livia, Schmid, Martin K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546020/
https://www.ncbi.nlm.nih.gov/pubmed/26289356
http://dx.doi.org/10.1186/s12886-015-0101-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546020/
https://www.ncbi.nlm.nih.gov/pubmed/26289356
http://dx.doi.org/10.1186/s12886-015-0101-4

Ejemplares similares